RxDoctor Payments Data

Johnny Chahine, MD

Cardiovascular Disease · Albany, NYNPI 1528589652

Payments from drug & device makers

$1,844in general payments, 2019–2025

Across 42 payments — averaging $43.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$731
  • E.r. Squibb & Sons, L.L.C.$323
  • Medtronic$167
  • Heartflow, Inc.$101
  • Tetraphase Pharmaceuticals, Inc.$95
  • Kiniksa Pharmaceuticals International, PLC$87
  • plus $340 from 8 others

What the payments were for

  • Travel & lodging$231%
  • Food & beverage$1,44578%
  • Education$37520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,844 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$100,127
Medicare patients
1,084
Services billed
1,867

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$90,251
EntrestoSacubitril/Valsartan16$17,445
XareltoRivaroxaban12$7,876
Rosuvastatin Calcium47$1,744
Atorvastatin Calcium156$1,267
Ezetimibe40$938
Carvedilol82$766
Metoprolol Succinate56$678
Torsemide22$526
Amlodipine Besylate72$323
Losartan Potassium33$262
Pravastatin Sodium22$254
Isosorbide Mononitrate ErIsosorbide Mononitrate31$228
Nitroglycerin13$220
Hydrochlorothiazide36$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$90,251103 claims
NovartisEntresto$62$17,44516 claims
Johnson & JohnsonXarelto$53$7,87612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →